Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-filled blisters.

Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Initial phase 2 data show improvement in Bullous ...

Researchers identified three different clusters of bullous pemphigoid, the most common autoimmune blistering disorder, according to a study published in the Journal of American Academy of Dermatology.

Bullous pemphigoid (BP) is a condition that affects the skin with an autoimmune etiology. It is often seen in those over the age of 80 and the prevalence is even higher in elderly people with ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

It's itchy, very painful and potentially fatal but a new clinical trial by University of Nottingham scientists is hoping to give sufferers of a rare skin condition a safe and effective treatment at ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA) to treat adults with bullous pemphigoid (BP). BP is a chronic and ...